



# ASX Release

EMVision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

## EMVISION RECEIVES \$2.58M R&D REBATE & ASA MILESTONE ACHIEVED

**EMVision Medical Devices Limited (ASX:EMV)** (“EMVision” or the “Company”), is pleased to advise that the Company has received a cash rebate of \$2,586,350 from its R&D tax incentive claim for the financial year ending 30 June 2023 and triggered a \$600,000 non-dilutive milestone payment.

The Australian Federal Government’s R&D Tax Incentive Program provides a cash refund on eligible research and development activities performed by Australian companies.

EMVision has achieved an important milestone under its Project Agreement with the Australian Stroke Alliance (ASA), which is funded by the Commonwealth of Australia’s Medical Research Future Fund (MRFF), “Algorithm validation study – patient enrolment completed”. EMVision has submitted the required documentation to the ASA to trigger a further \$600,000 non-dilutive milestone payment.

Authorised for release by the Chairman and Managing Director of the Company.

**[ENDS]**

For further information, media or investor enquiries, please contact:

Andrew Keys  
Investor Relations  
+61 400 400 800  
andrew.keys@keysthomas.com

Sling & Stone  
Media and Communications  
emvision@slingstone.com  
02 8073 5390

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

## **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

## **Inherent risks of Investment in Medical Device development Companies**

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.